Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Operating Leases (2019 - 2025)

Amphastar Pharmaceuticals (AMPH) has 7 years of Operating Leases data on record, last reported at $39.4 million in Q3 2025.

  • For Q3 2025, Operating Leases rose 36.28% year-over-year to $39.4 million; the TTM value through Sep 2025 reached $39.4 million, up 36.28%, while the annual FY2024 figure was $41.9 million, 40.91% up from the prior year.
  • Operating Leases reached $39.4 million in Q3 2025 per AMPH's latest filing, up from $39.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $41.9 million in Q4 2024 and bottomed at $16.5 million in Q1 2021.
  • Average Operating Leases over 5 years is $28.7 million, with a median of $25.5 million recorded in 2022.
  • Peak YoY movement for Operating Leases: soared 54.82% in 2022, then decreased 5.87% in 2023.
  • A 5-year view of Operating Leases shows it stood at $24.7 million in 2021, then fell by 4.08% to $23.7 million in 2022, then increased by 25.44% to $29.7 million in 2023, then skyrocketed by 40.91% to $41.9 million in 2024, then decreased by 5.83% to $39.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $39.4 million in Q3 2025, $39.0 million in Q2 2025, and $40.7 million in Q1 2025.